Supplementary data

Design, synthesis, and evaluation of A-ring-modified lamellarin N analogues as noncovalent inhibitors of the EGFR T790M/L858R mutant

Tsutomu Fukuda ^a, Teppei Umeki ^a, Keiji Tokushima ^a, Gao Xiang ^a, Yuki Yoshida ^a, Fumito Ishibashi ^b, Yusuke Oku ^c, Naoyuki Nishiya ^c, Yoshimasa Uehara ^c, Masatomo Iwao ^{a,*}

^a Division of Chemistry and Materials Science, Graduate School of Engineering, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

^b Division of Marine Life Science and Biochemistry, Graduate School of Fisheries and Environmental Sciences, Nagasaki University,

1-14 Bunkyo-machi, Nagasaki 852-8521, Japan

^c Department of Integrated Information for Pharmaceutical Sciences, Iwate Medical University School of Pharmacy, 2-1-1 Nishitokuta, Yahaba-cho, Shiwa-gun, Iwate 028-3694, Japan

List of Contents

Experimental data for 8a–g	S2–S10
References	S10–S11
¹ H and ¹³ C NMR spectra	S12–S163

Synthesis of arylboronic acids 8a-g.



1-Bromo-2-(methoxymethoxy)benzene (S1). Under an argon atmosphere, chloromethyl methyl ether (1.98 mL, 26.0 mmol) was added dropwise to a solution of 2-bromophenol (3.00 g, 17.3 mmol) and *N*,*N*-diisopropylethylamine (6.04 mL, 34.7 mmol) in dichloromethane (60 mL) at 0 °C. After stirring for 1 h, the reaction mixture

was allowed to warm to room temperature and stirred for an additional 20 h. The mixture was quenched with saturated aqueous ammonia and the products were extract with dichloromethane. The extract was washed with 10% aqueous NaOH, water, and brine, dried over Na₂SO₄, and evaporated. The residue was purified by bulb-to-bulb distillation (95–110 °C, 5 mmHg) to give **S1** as colorless oil (3.58 g, 95%). ¹H NMR (500 MHz, CDCl₃): δ 3.53 (s, 3H), 5.25 (s, 2H), 6.89 (ddd, J = 1.5, 7.4, and 7.9 Hz, 1H), 7.15 (dd, J = 1.5 and 8.3 Hz, 1H), 7.25 (ddd, J = 1.6, 7.4, and 8.3 Hz, 1H), 7.54 (dd, J = 1.6 and 7.9 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃): δ 56.4, 95.1, 112.9, 116.2, 123.1, 128.5, 133.4, 153.8. HREIMS *m/z* calcd for C₈H₉BrO₂ (H⁺): 215.9786, found 215.9790. These physical and spectroscopic data are in good agreement with those previously reported.¹



2-(Methoxymethoxy)phenylboronic acid (8a). Under an argon atmosphere, a pentane solution of *tert*-butyllithium (1.52 M, 14.4 mL, 21.9 mmol) was added dropwise to a solution of **S1** (2.38 g, 11.0 mmol) in THF (30 mL) at -78 °C. After stirring for 1 h at -78 °C, trimethyl borate (1.84 mL, 16.5 mmol) was added as a

neat liquid and the mixture was stirred for 1 h at -78 °C. The reaction mixture was allowed to warm to room temperature and stirred for an additional 1 h. The mixture was quenched with saturated aqueous NH₄Cl and concentrated. The products were adjusted to pH 3 with acetic acid and the mixture was extract with dichloromethane. The extract was washed successively with water and brine, dried over Na₂SO₄, and evaporated. The residue was washed with hexane and dried under reduced pressure to give **8a** as a colorless powder (1.41 g, 71%). This compound was used for the next reaction without further purification. This compound was used for the next reaction without further purification. Mp 65–66 °C. IR (KBr): 3372, 1601, 1484, 1455, 1398, 1341, 1159, 967 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.51 (s, 3H), 5.30 (s, 2H), 6.13 (s, 2H), 7.08 (dt, *J* = 0.8 and 7.3 Hz, 1H), 7.13 (d, *J* = 8.3 Hz, 1H), 7.43 (ddd, *J* = 1.9, 7.3, and 8.3 Hz, 1H), 7.87 (dd, *J* = 1.9 and 7.3 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃): δ 56.5, 94.6, 113.4, 122.3, 132.9, 136.8, 162.4. HREIMS *m/z* calcd for C₈H₁₁BO₄ (H⁺): 182.0750, found 182.0754.

OMe OMe OMOM S2 **1,2-Dimethoxy-4-(methoxymethoxy)benzene (S2).** According to the procedure described for the preparation of **S1**, 3,4-dimethoxyphenol (5.00 g, 32.4 mmol) was reacted. After purification by bulb-to-bulb distillation (120 °C/1 mmHg), **S2** was

obtained as a colorless oil (4.72 g, 73%). ¹H NMR (500 MHz, CDCl₃): δ 3.49 (s, 3H), 3.84 (s, 3H), 3.86 (s, 3H), 5.12 (s, 2H), 6.59 (dd, J = 2.7 and 8.7 Hz, 1H), 6.64 (d, J = 2.7 Hz, 1H), 6.78 (d, J =8.7 Hz, 1H). ¹³C NMR (126 MHz, CDCl₃): δ 55.9, 55.9, 56.4, 95.3, 102.1, 106.8, 111.8, 144.3, 149.7, 151.7. HRDARTMS m/z. Calcd for C₁₀H₁₅O₄ [(M+H)⁺]: 199.09703. Found: 199.09628. These physical and spectroscopic data are in good agreement with those previously reported.^{2,3}

OMe B ÓMOM **S**3

1-Bromo-4,5-dimethoxy-2-(methoxymethoxy)benzene (S3). A solution of NBS (8.98 g, 50.4 mmol) in DMF (15 mL) was added dropwise to a solution of S2 (10.0 g, 50.4 mmol) in DMF (15 mL) at 0 °C. After being stirred for 0.5 h, the reaction mixture was guenched with water at the same temperature and allowed to warm to room temperature. The products were extracted with diethyl ether and the extract was washed with brine, dried over Na₂SO₄, and evaporated. The residue was purified by column chromatography

(hexane-ethyl acetate = 3:1) to give S3 as a reddish brown solid (11.7 g, 84%). This compound was somewhat unstable and used for the next reaction without further purification. IR (KBr): 1509, 1373, 1211, 1150, 1010 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 3.55 (s, 3H), 3.84 (s, 3H), 3.86 (s, 3H), 5.17 (s, 2H), 6.80 (s, 1H), 7.01 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 56.2, 56.5, 56.5, 96.4, 102.6, 102.6, 115.7, 144.9, 148.0, 149.0. HRDARTMS m/z. Calcd for C₁₀H₁₄BrO₄ [(M+H)⁺]: 277.00755. Found: 277.00644. These physical and spectroscopic data are in good agreement with those previously reported.⁴



4,5-Dimethoxy-2-(methoxymethoxy)phenylboronic acid (8b). According to the procedure described for the preparation of 8a, S3 (6.20 g, 22.4 mmol) was reacted to give **8b** as a pale brown solid (3.44 g, 60%). This compound was used for the next reaction without further purification. Mp 83-85 °C. IR (KBr): 3484, 3427,

3218, 1608, 1514, 1400, 1312, 1212, 1149, 1001 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.52 (s, 3H), 3.89 (s, 3H), 3.91 (s, 3H), 5.25 (s, 2H), 6.05 (s, 2H), 6.78 (s, 1H), 7.30 (s, 1H). ¹³C NMR (126 MHz, CDCl₃): δ 55.9, 56.2, 56.5, 95.6, 99.1, 117.6, 144.2, 152.5, 157.8. HRDARTMS m/z. Calcd for $C_{10}H_{16}BO_6 [(M+H)^+]$: 243.10399. Found: 243.10396.

ÓMOM S4

5-Methoxymethoxy-1,3-benzodioxole (S4). According to the procedure described for the preparation of S1, sesamol (2.40 g, 17.3 mmol) was reacted. After purification by bulb-to-bulb distillation (80-85 °C/0.2 mmHg), S4 was obtained as a colorless oil (2.47 g, 78%). IR (KBr): 1487, 1178, 1152, 1070, 1006 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 3.47

(s, 3H), 5.08 (s, 2H), 5.92 (s, 2H), 6.49 (dd, J = 2.4 and 8.4 Hz, 1H), 6.62 (d, J = 2.4 Hz, 1H), 6.70 (d, J = 8.4 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 55.9, 95.5, 99.8, 101.2, 108.0, 108.5, 142.6, 148.1, 152.5. HRDARTMS m/z. Calcd for C₉H₁₁O₄ [(M+H)⁺]: 183.06573. Found: 183.06309. These physical and spectroscopic data are in good agreement with those previously reported.⁵



5-Bromo-6-methoxymethoxy-1,3-benzodioxole (S5). According to the procedure described for the preparation of **S3**, **S4** (1.82 g, 10.0 mmol) and NBS (2.67 g, 15.0 mmol) were reacted. After purification by column chromatography over silica gel 60N (hexane–ethyl acetate = 5:1), **S5** was obtained as a colorless solid (2.74 g, 87%). This

compound was somewhat unstable and used for the next reaction without further purification. ¹H NMR (400 MHz, CDCl₃): δ 3.53 (s, 3H), 5.13 (s, 2H), 5.95 (s, 2H), 6.78 (s, 1H), 6.98 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 56.4, 96.3, 100.1, 101.9, 103.3, 112.3, 143.2, 147.7, 148.7. These physical and spectroscopic data are in good agreement with those previously reported.⁶



(6-Methoxymethoxy-1,3-benzodioxol-5-yl)boronic acid (8c). Under an argon atmosphere, a pentane solution of *n*-butyllithium (1.59 M, 16.5 mL, 26.2 mmol) was added dropwise to a solution of S5 (6.20 g, 23.8 mmol) in THF (200 mL) at -100 °C. After stirring for 5 min, trimethyl borate (4.01 mL, 35.8 mmol) was added

as a neat liquid and the mixture was stirred for 0.5 h at -100 °C. The reaction mixture was allowed to warm to room temperature and stirred for an additional 1 h. The mixture was quenched with saturated aqueous NH₄Cl and concentrated. The products were adjusted to pH 3 with acetic acid and the mixture was extract with dichloromethane. The extract was washed successively with water, saturated aqueous NaHCO₃, and brine, dried over Na₂SO₄, and evaporated. The residue was washed with hexane and dried under reduced pressure to give **8c** as a colorless powder (3.09 g, 65%). This compound was used for the next reaction without further purification. Mp 95–105 °C. IR (KBr) 3353, 1623, 1434, 1328, 1155, 1001, 925 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 3.50 (s, 3H), 5.22 (s, 2H), 5.96 (s, 2H), 6.40 (s, 2H), 6.77 (s, 1H), 7.25 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 56.5, 95.5, 97.2, 101.5, 114.1, 114.6, 142.6, 151.1, 158.7. HREIMS *m/z*. Calcd for C₉H₁₁BO₆ (M⁺): 226.0649. Found: 226.0635.



4-Benzyloxy-5-methoxy-2-(methoxymethoxy)phenylboronic acid (8d). This compound was synthesized according to the previously reported procedure.⁷

OBn OMe CHO S6 **4-Benzyloxy-3-methoxybenzaldehyde (S6).** A neat liquid of benzyl bromide (43.2 mL, 361 mmol) was added to a suspension of vanillin (50.0 g, 329 mmol) and K_2CO_3 (50.0 g, 361 mmol) in acetone (500 mL) at room temperature and the mixture was refluxed for 12 h. The reaction mixture was cooled to room temperature and then filtered. The

filtrate was evaporated and the residue was diluted with diethyl ether. The mixture was washed with with 10% aqueous NaOH, water, and brine, dried over Na₂SO₄, and evaporated. The residue was recrystallized from diethyl ether–hexane to give **S6** as pale yellow granules (52.8 g, 66%). The mother liquor from the above recrystallization was evaporated and the residue was purified by bulb-to-bulb distillation (175–185 °C, 0.7 mmHg) to give an additional **S6** as pale yellow solid (8.49 g, 11%). The total yield of **S6** was 61.3 g (77%). Mp 60–61 °C (lit.⁸ 60–61 °C). IR (KBr): 1675, 1583, 1506, 1260, 1236, 1134 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 3.95 (s, 3H), 5.25 (s, 2H), 6.99 (d, *J* = 8.2 Hz, 1H), 7.29–7.35 (m, 1H), 7.36–7.41 (m, 3H), 7.42–7.46 (m, 3H), 9.83 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 56.1, 70.9, 109.3, 112.4, 126.6, 127.2, 128.2, 128.7, 130.3, 136.0, 150.1, 153.6, 190.9. HRDARTMS *m/z*. Calcd for C₁₅H₁₅O₃ [(M+H)⁺]: 243.10212. Found: 243.10258. These physical and spectroscopic data are in good agreement with those previously reported.⁸

4-Benzyloxy-3-methoxyphenol (S7). Under an argon atmosphere, *m*-chloroperbenzoic OBn OMe acid (contains ca 30% water, purity >65%, 41.7 g, ca. 157 mmol) was added portionwise to a solution of S6 (25.3 g, 105 mmol) in dichloromethane (160 mL) at 0 °C. ÓН **S**7 After stirring for 7.5 h, the reaction mixture was quenched with saturated aqueous NaHCO₃. The mixture was diluted with water and the organic layer was separated. The aqueous layer was extracted with dichloromethane. The combined extracts were washed with saturated aqueous NaHCO₃, water, and brine, dried over Na₂SO₄, and evaporated. The residue was dissolved in methanol (300 mL) and K₂CO₃ (72.3 g, 523 mmol) was added portionwise to the solution at room temperature. After stirring for 1 h, the mixture was evaporated under reduced pressure. Water was added to the residue and the product was extracted with diethyl ether. The extract was washed with water and brine, dried over Na₂SO₄, and evaporated. The residue was recrystallized from diethyl ether-hexane to give S7 as pale yellow granules (14.7 g, 61%). The mother liquor from the above recrystallization was evaporated and the residue was chromatographed over silica gel 60N (hexane-ethyl acetate = 3:1) to give an additional S7 as pale yellow solid (3.14 g, 13%). The total yield of **S7** was 17.8 g (74%). Mp 82.5–83.5 °C (lit.⁹ 85–86 °C). IR (KBr): 3303, 1514, 1448, 1222, 1195, 1122 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 3.81 (s, 3H), 4.93 (s, 1H), 5.05 (s, 2H), 6.25 (dd, J = 2.8 and 8.5 Hz, 1H), 6.45 (d, J = 2.8 Hz, 1H), 6.72 (d, J = 8.5 Hz, 1H), 7.26–7.31 (m, 1H), 7.32–7.37 (m, 2H), 7.39–7.43 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 55.9, 72.3, 100.8, 106.0, 116.3, 127.5, 127.8, 128.4, 137.4, 142.1, 150.7, 150.9. HRDARTMS m/z. Calcd for C₁₄H₁₅O₃ [(M+H)⁺]: 231.10212. Found: 231.10067. These physical and spectroscopic data are in good agreement with those previously reported.⁹

1-Benzyloxy-2-methoxy-4-(methoxymethoxy)benzene (S8). According to the OBn OMe procedure described for the preparation of S1, S7 (8.65 g, 37.6 mmol) was reacted. After purification by by column chromatography (hexane-ethyl acetate = 4:1), S8 was ÓMOM **S**8 obtained as colorless solid (8.87 86%). Recrystallization а g, from dichloromethane-hexane gave a colorless granules. Mp 42 °C. IR (KBr): 1515, 1217, 1149, 1135, 1024, 1007 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.48 (s, 3H), 3.86 (s, 3H), 5.08 (s, 2H), 5.11 (s, 2H), 6.51 (dd, J = 2.8 and 8.7 Hz, 1H), 6.64 (d, J = 2.8 Hz, 1H), 6.79 (d, J = 8.7 Hz, 1H), 7.27–7.31 (m, 1H), 7.33–7.38 (m, 2H), 7.41–7.45 (m, 2H). ¹³C NMR (126 MHz, CDCl₃): δ 56.0, 72.0, 95.2, 102.3, 106.9, 115.5, 127.4, 127.8, 128.5, 137.5, 143.3, 150.7, 152.3. HRDARTMS m/z. Calcd for $C_{16}H_{19}O_4$ [(M+H)⁺]: 275.12833. Found: 275.12851.

1-Benzyloxy-5-bromo-2-methoxy-4-(methoxymethoxy)benzene (S9). According to the procedure described for the preparation of **S3**, **S8** (2.54 g, 9.26 mmol) and NBS (1.81 g, 10.2 mmol) were reacted. After purification by column chromatography over silica gel 60N (hexane–ethyl acetate = 3:1), **S9** was obtained as a pale yellow solid (2.92 g, 90%). This compound was somewhat unstable and used for the next reaction without further purification. Mp 53–54 °C. ¹H NMR (400 MHz, CDCl₃): δ 3.54 (s, 3H), 3.86 (s, 3H), 5.06 (s, 2H), 5.17 (s, 2H), 6.81 (s, 1H), 7.06 (s, 1H), 7.28–7.34 (m, 1H), 7.34–7.40 (m, 2H), 7.40–7.45 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 56.3, 56.5, 72.0, 96.3, 102.4, 102.8, 119.0, 127.5, 128.0, 128.6, 136.7, 144.0, 148.6, 150.0. HRDARTMS *m/z*. Calcd for C₁₆H₁₈BrO4 [(M+H)⁺]: 353.03885. Found: 353.03779.

5-Benzyloxy-4-methoxy-2-(methoxymethoxy)phenylboronic acid (8e). OBn OMe According to the procedure described for the preparation of **8b**, **S9** (2.82 g, 7.99 (HO)₂B mmol) was reacted to give 8e as a pale yellow powder (2.01 g, 79%). This ÓMOM 8e compound was used for the next reaction without further purification. Mp 88–90 °C. IR (KBr): 3329, 1604, 1513, 1397, 1205, 1151, 1006 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.51 (s, 3H), 3.89 (s, 3H), 5.11 (s, 2H), 5.24 (s, 2H), 5.99 (s, 2H), 6.78 (s, 1H), 7.27–7.32 (m, 1H), 7.33–7.38 (m, 2H), 7.39 (s, 1H), 7.44–7.47 (m, 2H). ¹³C NMR (126 MHz, CDCl₃): δ 56.0, 56.5, 71.6, 95.5, 99.4, 121.0, 127.6, 127.8, 128.5, 137.3, 143.3, 153.4, 158.3. HREIMS m/z. Calcd for C₁₆H₁₉BO₆ (M⁺): 318.1275. Found: 318.1277.

Oi-Pr OH CHO S10 **3-Hydroxy-4-isopropoxybenzaldehyde (S10).** A neat liquid of 2-bromopropane (4.42 mL, 47.1 mmol) was added to a suspension of 3,4-dihydroxybenzaldehyde (5.01 g, 36.3 mmol), KI (6.02 g, 36.3 mmol), and K_2CO_3 (5.01 g, 36.2 mmol) in DMF (30 mL) at 40 °C. After stirring for 21 h at 40 °C, the reaction mixture was cooled to 0 °C and

quenched with 2 M HCl until bubbling subsided. The mixture was extracted with ethyl acetate and the extract was washed with water, and brine, dried over Na₂SO₄, and evaporated. The residue was purified by column chromatography over silica gel 60N (hexane–ethyl acetate = 5:1) to give **S10** as a pale yellow granules (4.25 g, 65%). Recrystallization from Et₂O–hexane gave a colorless needles. Mp 65.5–66.5 °C (lit.¹⁰ 69–70 °C). IR (KBr): 1673, 1505, 1274, 1126, 1104 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.42 (d, *J* = 6.1 Hz, 6H), 4.74 (sep, *J* = 6.1 Hz, 1H), 5.93 (s, 1H), 6.96 (d, *J* = 8.2 Hz, 1H), 7.41 (dd, *J* = 2.0 and 8.2 Hz, 1H), 7.45 (d, *J* = 2.0 Hz, 1H), 9.83 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 22.0, 71.9, 111.9, 114.3, 124.3, 130.2, 146.7, 150.1, 191.0. HRDARTMS *m/z*. Calcd for C₁₀H₁₃O₃ [(M+H)⁺]: 181.08647. Found: 181.08351. These physical and spectroscopic data are in good agreement with those previously reported.¹⁰

3-Benzyloxy-4-isopropoxybenzaldehyde (S11). According to the procedure described Oi-Pr .OBn for the preparation of S6, a mixture of 3-hydroxy-4-isopropoxybenzaldehyde (3.89 g, 21.6 mmol), benzyl bromide (3.33 mL, 28.0 mmol), and K₂CO₃ (3.87 g, 28.0 mmol) in ĊНО S11 acetone (40 mL) was refluxed for 22 h. After purification by chromatography over silica gel 60N (hexane-ethyl acetate), S11 was obtained as a colorless solid (5.71 g, 98%). Bp 150–155 °C (0.1 mmHg, bulb-to-bulb). Mp 34.5–35.5 °C (lit.¹⁰ 37.5–38 °C). IR (KBr): 1688, 1595, 1579, 1506, 1269, 1132 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.41 (d, J = 6.1 Hz, 6H), 4.68 (sep, J= 6.1 Hz, 1H), 5.17 (s, 2H), 7.00 (d, J = 8.2 Hz, 1H), 7.28–7.33 (m, 1H), 7.34–7.40 (m, 2H), 7.42–7.47 (m, 4H), 9.80 (s, 1H). ¹³C NMR (100 MHz, CDCl₃): δ 22.0, 71.0, 71.7, 113.1, 114.1, 126.7, 127.2, 127.9, 128.5, 129.9, 136.7, 149.6, 154.0, 190.8. HRDARTMS m/z. Calcd for $C_{17}H_{19}O_3$ [(M+H)⁺]: 271.13342. Found: 271.13063. These physical and spectroscopic data are in good agreement with those previously reported.¹⁰

3-Benzyloxy-4-isopropoxyphenol (S12). According to the procedure described for the preparation of **S7**, **S11** (3.00 g, 11.1 mmol) was reacted. After purification by column chromatography over silica gel 60N (hexane–ethyl acetate = 3:1), **S12** was obtained as a pale yellow solid (2.23 g, 78%). Recrystallization from Et₂O–hexane gave pale yellow granules. Mp 111–112 °C. IR (KBr): 3294, 1604, 1511, 1452, 1220, 1205, 1177, 1102 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.29 (d, J = 6.1 Hz, 6H), 4.34 (sep, J = 6.1 Hz, 1H), 5.01 (s, 2H), 5.13 (br s, 1H), 6.31 (dd, J = 2.8 and 8.6 Hz, 1H), 6.45 (d, J = 2.8 Hz, 1H), 6.80 (d, J = 8.6 Hz, 1H), 7.26–7.32 (m, 1H), 7.32–7.38 (m, 2H), 7.38–7.43 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 22.3, 70.8, 73.8, 103.1, 107.1, 120.8, 127.2, 127.8, 128.5, 137.1, 141.3, 151.2, 151.3. *Anal.* Calcd for C₁₆H₁₈O₃: C, 74.40; H, 7.02. Found: C, 74.34; H, 6.94.

2-Benzyloxy-1-isopropoxy-4-(methoxymethoxy)benzene (S13). According to the procedure described for the preparation of **S1**, **S12** (785 mg, 3.04 mmol) was reacted. After purification by column chromatography over silica gel 60N (hexane–ethyl acetate = 5:1), **S13** was obtained as a colorless solid (856 mg, 93%). Bp 200–210 °C (3 mmHg, bulb-to-bulb). IR (KBr): 1506, 1260, 1221, 1153, 1020 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.31 (d, J = 6.1 Hz, 6H), 3.45 (s, 3H), 4.38 (sep, J = 6.1 Hz, 1H), 5.08 (s, 2H), 5.09 (s, 2H), 6.57 (dd, J = 2.8 and 8.7 Hz, 1H), 6.68 (d, J = 2.8 Hz, 1H), 6.86 (d, J = 8.7 Hz, 1H), 7.27–7.33 (m, 1H), 7.33–7.40 (m, 2H), 7.42–7.47 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 22.3, 55.9, 71.0, 73.3, 95.1, 104.9, 108.1, 119.9, 127.3, 127.7, 128.4, 137.2, 142.9, 151.0, 152.6. HRDARTMS *m/z*. Calcd for C₁₈H₂₃O₄ [(M+H)⁺]: 303.15963. Found: 303.15982.

O/-Pr Br OBn OMOM S14

Oi-Pr

ÓМОМ

8f

 $(HO)_2B$

OBn

ĊНО S15 **1-Benzyloxy-4-bromo-2-isopropoxy-5-(methoxymethoxy)benzene**(S14).According to the procedure described for the preparation of S3, S13 (600 mg, 1.98 mmol) and NBS (352 mg, 1.98 mmol) were reacted. After purification by column chromatography over silica gel 60N (hexane–ethyl acetate = 10:1), S14 was obtained

as a colorless solid (725 mg, 96%). This compound was somewhat unstable and used for the next reaction without further purification. IR (KBr): 1505, 1374, 1202, 1152, 1007 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.32 (d, *J* = 6.0 Hz, 6H), 3.48 (s, 3H), 4.40 (sep, *J* = 6.0 Hz, 1H), 5.09 (s, 2H), 5.10 (s, 2H), 6.83 (s, 1H), 7.10 (s, 1H), 7.27–7.33 (m, 1H), 7.33–7.40 (m, 2H), 7.40–7.46 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 22.2, 56.3, 71.5, 73.4, 96.1, 103.3, 105.8, 122.7, 127.4, 127.9, 128.5, 136.8, 143.7, 148.7, 150.0. HRDARTMS *m*/*z*. Calcd for C₁₈H₂₂BrO₄ [(M+H)⁺]: 381.07015. Found: 381.07031.

4-Benzyloxy-5-isopropoxy-2-(methoxymethoxy)phenylboronic acid (8f).
According to the procedure described for the preparation of 8c, S14 (574 mg, 1.51 mmol) was reacted to give 8f as a colorless solid (367 mg, 70%). This compound was used for the next reaction without further purification. Mp 92–93.5 °C. IR

(KBr): 1602, 1509, 1420, 1397, 1316, 1204, 1155, 1006 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ 1.32 (d, *J* = 6.1 Hz, 6H), 3.46 (s, 3H), 4.45 (sep, *J* = 6.1 Hz, 1H), 5.15 (s, 2H), 5.16 (s, 2H), 6.30 (s, 1H), 6.33 (s, 1H), 6.81 (s, 1H), 7.27–7.33 (m, 1H), 7.34–7.39 (m, 2H), 7.40 (s, 1H), 7.42–7.47 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 22.3, 56.3, 70.8, 73.0, 95.4, 102.0, 125.5, 127.3, 127.9, 128.5, 136.8, 142.8, 153.5, 158.2. HREIMS *m/z*. Calcd for C₁₈H₂₃BO₆ (M⁺): 346.1588. Found: 346.1581.

OBn **3,4-Bis(benzyloxy)benzaldehyde (S15).** According to the procedure described for the preparation of **S6**, a mixture of 3,4-dihydroxybenzaldehyde (5.53 g, 40.0 mmol), benzyl bromide (9.50 mL, 80 mmol), and K₂CO₃ (11.6 g, 84.0 mmol) in acetone (400 mL) was

refluxed for 21 h. The crude product was recrystallized from dichloromethane–hexane to give **S15** as a colorless granules (9.39 g, 73%). The mother liquor from the above recrystallization was evaporated and the residue was chromatographed over silica gel 60N (hexane–ethyl acetate = 5:1) to give an additional **S15** as a colorless yellow solid (332 mg, 3%). The total yield of **S15** was 9.72 g (76%). Mp 83.5–84 °C (lit.¹¹ 88–89 °C). IR (KBr): 1677, 1596, 1512, 1435, 1282, 1135 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 5.21 (s, 2H), 5.25 (s, 2H), 7.02 (d, *J* = 8.2 Hz, 1H), 7.29–7.35 (m, 2H), 7.35–7.40 (m, 4H), 7.41 (dd, *J* = 1.9 and 8.2 Hz, 1H), 7.43–7.48 (m, 4H), 7.49 (d, *J* = 1.9 Hz, 1H), 9.81 (s, 1H). ¹³C NMR (126 MHz, CDCl₃): δ 70.8, 71.0, 112.4, 113.1, 126.7, 127.1, 127.3, 128.0, 128.1, 128.6, 128.7, 130.3, 136.2, 136.5, 149.2, 154.3, 190.8. HRDARTMS *m/z*. Calcd for C₂₁H₁₉O₃ [(M+H)⁺]: 319.13342. Found: 319.13108. These physical and spectroscopic data are in good agreement with those previously reported.^{11,12}

3,4-Bis(benzyloxy)phenol (S16). According to the procedure described for the preparation of **S7**, **S15** (8.36 g, 29.2 mmol) was reacted. After recrystallization from dichloromethane–hexane, **S16** was obtained as a pale yellow granules (6.93 g, 86%). Mp 103.5–104.5 °C (lit.¹² 102–104 °C). IR (KBr): 3294, 1609, 1508, 1455, 1380, 1213, 1124, 1004 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.94 (br s, 1H), 5.04 (s, 2H), 5.07 (s, 2H), 6.28 (dd, J = 2.8 and 8.6 Hz, 1H), 6.48 (d, J = 2.8 Hz, 1H), 6.78 (d, J = 8.6 Hz, 1H), 7.26–7.37 (m, 6H), 7.38–7.43 (m, 4H). ¹³C NMR (126 MHz, CDCl₃): δ 71.0, 72.8, 103.3, 107.0, 117.6, 127.3, 127.6, 127.8, 127.9, 128.4, 128.5, 137.0, 137.6, 142.7, 150.3, 150.9. HRDARTMS *m/z*. Calcd for C₂₀H₁₉O₃ [(M+H)⁺]: 307.13342. Found: 307.13631. These physical and spectroscopic data are in good agreement with those previously reported.^{11,12}

1,2-Bis(benzyloxy)-4-(methoxymethoxy)benzene (S17). According to the procedure described for the preparation of **S1**, **S16** (8.65 g, 37.6 mmol) was reacted. After purification by column chromatography (hexane–ethyl acetate = 4:1), **S17** was obtained as a colorless solid (8.87 g, 86%). Recrystallization from Et₂O–hexane gave colorless needles. Mp 50–51 °C. IR (KBr): 1595, 1511, 1218, 1150, 1131, 1010 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.44 (s, 3H), 5.07 (s, 2H), 5.08 (s, 2H), 5.13 (s, 2H), 6.55 (dd, J = 2.8 and 8.8 Hz, 1H), 6.70 (d, J = 2.8 Hz, 1H), 6.85 (d, J = 8.8 Hz, 1H), 7.26–7.39 (m, 6H), 7.40–7.47 (m, 4H). ¹³C NMR (126 MHz, CDCl₃): δ 55.9, 71.1, 72.4, 95.2, 104.9, 108.0, 116.8, 127.4, 127.5, 127.7, 127.8, 128.4, 128.5, 137.1, 137.6, 144.0, 150.0, 152.4. HRDARTMS *m/z*. Calcd for C₂₂H₂₃O₄ [(M+H)⁺]: 351.15963. Found: 351.16166. These physical and spectroscopic data are in good agreement with those previously reported.¹¹



1,2-Bis(benzyloxy)-5-bromo-4-(methoxymethoxy)benzene (S18). According to the OBn procedure described for the preparation of S3, S17 (1.00 g, 2.85 mmol) and NBS (533 mg, 2.99 mmol) were reacted. After purification by column chromatography over silica gel 60N (hexane-ethyl acetate = 10:1), S18 was obtained as a colorless solid (978 mg, 80%). This compound was somewhat unstable and used for the next reaction without further purification. Mp 38–39 °C. ¹H NMR (400 MHz, CDCl₃): δ 3.48 (s, 3H), 5.07 (s, 2H), 5.09 (s, 2H), 5.12 (s, 2H), 6.86 (s, 1H), 7.11 (s, 1H), 7.27–7.39 (m, 6H), 7.39–7.45 (m, 4H). ¹³C NMR (100 MHz, CDCl₃): δ 56.3, 71.6, 72.4, 96.1, 103.3, 105.8, 120.1, 127.5, 128.0, 128.0, 128.5, 136.7, 136.9, 144.7, 148.7, 149.0. HRDARTMS m/z. Calcd for C₂₂H₂₂BrO₄ [(M+H)⁺]: 429.07015. Found: 429.07178.



4,5-Bis(benzyloxy)-2-(methoxymethoxy)phenylboronic acid (8g). According to the procedure described for the preparation of 8c, S18 (1.22 g, 2.87 mmol) was reacted to give 8g as a colorless solid (905 mg, 80%). This compound was used for the next reaction without further purification. Mp 106–109 °C. IR (KBr): 3310,

1602, 1512, 1421, 1396, 1319, 1215, 1150, 1017 cm⁻¹. ¹H NMR (500 MHz, CDCl₃): δ 3.46 (s, 3H), 5.12 (s, 2H), 5.16 (s, 2H), 5.18 (s, 2H), 5.93 (s, 2H), 6.83 (s, 1H), 7.27–7.39 (m, 6H), 7.43 (s, 1H), 7.43–7.47 (m, 4H). ¹³C NMR (126 MHz, CDCl₃): δ 56.3, 71.0, 72.0, 95.4, 102.0, 122.3, 127.4, 127.6, 127.8, 127.9, 128.4, 128.5, 136.7, 137.5, 143.9, 152.5, 158.2. HREIMS m/z. Calcd for C₂₂H₂₃BO₆ (M⁺): 394.1588. Found: 394.1589.

References

- 1. Deguchi, J.; Sasaki, T.; Hirasawa, Y.; Kaneda, T.; Kusumawari, I.; Shirota, O.; Morita, H. Tetrahedron Lett. 2014, 55, 1362–1365.
- Bishop, J. E.; Mathis, C. A.; Gerdes, J. M.; Whitney, J. M.; Eaton, A. M.; Mailman, R. B. J. 2. Med. Chem. 1991, 34, 1612–1624.
- Jiang, H.; Tian, L.; Li, Z.; Liu, Q.; Li, C.; Yao, X.; Yang, Z. Sci. China: Chem. 2012, 55, 3. 36-42.
- Donnelly, D. M. X.; Finet, J.-P.; Rattigan, B. A. J. Chem. Soc., Perkin Trans. 1 1995, 4. 1679–1683.
- Endo, A.; Yanagisawa, A.; Abe, M.; Tohma, S.; Kan, T.; Fukuyama, T. J. Am. Chem. Soc. 5. 2002, 124, 6552-6554.
- Worayuthakarn, R.; Boonya-udtayan, S.; Ruchirawat, S.; Thasana, N. Eur. J. Org. Chem. 2014, 6. 2496-2507.
- Kamiyama, H.; Kubo, Y.; Sato, H.; Yamamoto, N.; Fukuda, T.; Ishibashi, F.; Iwao, M. Bioorg. 7. Med. Chem. 2011, 19, 7541-7550.

- Ploypradith, P.; Cheryklin, P.; Niyomtham, N.; Bertoni, D. R.; Ruchirawat, S. Org. Lett. 2007, 9, 2637–2640.
- 9. Cruz, M. C.; Tamariz, J. *Tetrahedron* **2005**, *61*, 10061–10072.
- 10. Hewgill, F. R. Pass, M. C. Aust. J. Chem. 1985, 38, 537-554.
- 11. Li, C. C.; Xie, Z. X.; Zhang, Y. D.; Chen, J. H.; Yang, Z. J. Org. Chem. 2003, 68, 8500-8504.
- 12. Yamaguchi, S.; Machi, M.; Kinoshita, Y. Biosci. Biotechnol. Biochem. 1999, 63, 1453-1462.



Figure S1. ¹H NMR spectrum of compound **6** (400 MHz, CDCl₃).



Figure S2. ¹³C NMR spectrum of compound **6** (100 MHz, CDCl₃).



Figure S3. ¹H NMR spectrum of compound **7** (400 MHz, CDCl₃).



Figure S4. ¹³C NMR spectrum of compound **7** (100 MHz, CDCl₃).



Figure S5. ¹H NMR spectrum of compound 9a (400 MHz, CDCl₃).



Figure S6. ¹³C NMR spectrum of compound **9a** (100 MHz, CDCl₃).



Figure S7. ¹H NMR spectrum of compound **9b** (400 MHz, CDCl₃).



Figure S8. ¹³C NMR spectrum of compound 9b (100 MHz, CDCl₃).



Figure S9. ¹H NMR spectrum of compound **9c** (400 MHz, CDCl₃).



Figure S10. 13 C NMR spectrum of compound 9c (100 MHz, CDCl₃).



Figure S11. ¹H NMR spectrum of compound 9d (400 MHz, CDCl₃).



Figure S12. ¹³C NMR spectrum of compound **9d** (100 MHz, CDCl₃).



Figure S13. ¹H NMR spectrum of compound **9e** (400 MHz, CDCl₃).



Figure S14. 13 C NMR spectrum of compound 9e (100 MHz, CDCl₃).



Figure S15. ¹H NMR spectrum of compound **9f** (500 MHz, CDCl₃).



Figure S16. 13 C NMR spectrum of compound 9f (126 MHz, CDCl₃).



Figure S17. ¹H NMR spectrum of compound **9g** (500 MHz, CDCl₃).



Figure S18. 13 C NMR spectrum of compound 9g (126 MHz, CDCl₃).



Figure S19. ¹H NMR spectrum of compound 10a (400 MHz, CDCl₃).



Figure S20. 13 C NMR spectrum of compound 10a (100 MHz, CDCl₃).



Figure S21. ¹H NMR spectrum of compound 10b (400 MHz, CDCl₃).



Figure S22. 13 C NMR spectrum of compound 10b (100 MHz, CDCl₃).



Figure S23. ¹H NMR spectrum of compound 10c (400 MHz, CDCl₃).



Figure S24. 13 C NMR spectrum of compound 10c (100 MHz, CDCl₃).



Figure S25. ¹H NMR spectrum of compound 10d (400 MHz, CDCl₃).


Figure S26. 13 C NMR spectrum of compound 10d (100 MHz, CDCl₃).



Figure S27. ¹H NMR spectrum of compound 10e (400 MHz, CDCl₃).



Figure S28. ¹³C NMR spectrum of compound 10e (100 MHz, CDCl₃).



Figure S29. ¹H NMR spectrum of compound 10f (400 MHz, CDCl₃).



Figure S30. 13 C NMR spectrum of compound 10f (100 MHz, CDCl₃).



Figure S31. ¹H NMR spectrum of compound 10g (500 MHz, CDCl₃).



Figure S32. 13 C NMR spectrum of compound 10g (126 MHz, CDCl₃).



Figure S33. ¹H NMR spectrum of compound **11a** (500 MHz, DMSO- d_6).



Figure S34. ¹³C NMR spectrum of compound **11a** (126 MHz, DMSO- d_6).



Figure S35. ¹H NMR spectrum of compound 11b (400 MHz, DMSO-*d*₆).



Figure S36. ¹³C NMR spectrum of compound **11b** (100 MHz, DMSO- d_6).



Figure S37. ¹H NMR spectrum of compound **11c** (500 MHz, DMSO- d_6).



Figure S38. ¹³C NMR spectrum of compound **11c** (126 MHz, DMSO- d_6).



Figure S39. ¹H NMR spectrum of compound **11d** (500 MHz, DMSO-*d*₆).



Figure S40. ¹³C NMR spectrum of compound **11d** (126 MHz, DMSO- d_6).



Figure S41. ¹H NMR spectrum of compound **11e** (500 MHz, DMSO-*d*₆).



Figure S42. ¹³C NMR spectrum of compound **11e** (126 MHz, DMSO- d_6).



Figure S43. ¹H NMR spectrum of compound **12a** (400 MHz, CDCl₃).



Figure S44. 13 C NMR spectrum of compound 12a (100 MHz, CDCl₃).



Figure S45. ¹H NMR spectrum of compound 12b (500 MHz, DMSO-*d*₆).



Figure S46. ¹³C NMR spectrum of compound **12b** (126 MHz, DMSO- d_6).



Figure S47. ¹H NMR spectrum of compound 12c (400 MHz, CDCl₃).



Figure S48. 13 C NMR spectrum of compound 12c (100 MHz, CDCl₃).



Figure S49. ¹H NMR spectrum of compound **12d** (500 MHz, DMSO-*d*₆).



Figure S50. ¹³C NMR spectrum of compound 12d (126 MHz, DMSO- d_6).



Figure S51. ¹H NMR spectrum of compound 13a (400 MHz, CDCl₃).



Figure S52. 13 C NMR spectrum of compound 13a (100 MHz, CDCl₃).



Figure S53. ¹H NMR spectrum of compound 13b (400 MHz, CDCl₃).



Figure S54. 13 C NMR spectrum of compound 13b (100 MHz, CDCl₃).



Figure S55. ¹H NMR spectrum of compound 13c (500 MHz, CDCl₃).



Figure S56. 13 C NMR spectrum of compound 13c (126 MHz, CDCl₃).



Figure S57. ¹H NMR spectrum of compound 13d (500 MHz, CDCl₃).



Figure S58. 13 C NMR spectrum of compound 13d (126 MHz, CDCl₃).



Figure S59. ¹H NMR spectrum of compound 13e (500 MHz, CDCl₃).



Figure S60. 13 C NMR spectrum of compound 13e (126 MHz, CDCl₃).



Figure S61. ¹H NMR spectrum of compound 13f (500 MHz, CDCl₃).


Figure S62. ¹³C NMR spectrum of compound 13f (126 MHz, CDCl₃).



Figure S63. ¹H NMR spectrum of compound 13g (500 MHz, CDCl₃).



Figure S64. 13 C NMR spectrum of compound 13g (126 MHz, CDCl₃).



Figure S65. ¹H NMR spectrum of compound **14a**' (400 MHz, DMSO- d_6).



Figure S66. ¹³C NMR spectrum of compound **14a**' (100 MHz, DMSO- d_6).



Figure S67. ¹H NMR spectrum of compound **14a** (500 MHz, DMSO-*d*₆).



Figure S68. ¹³C NMR spectrum of compound 14a (126 MHz, DMSO- d_6).



Figure S69. ¹H NMR spectrum of compound **14b**' (500 MHz, DMSO- d_6).



Figure S70. ¹³C NMR spectrum of compound 14b' (126 MHz, DMSO- d_6).



Figure S71. ¹H NMR spectrum of compound 14b (500 MHz, DMSO-*d*₆).



Figure S72. ¹³C NMR spectrum of compound 14b (126 MHz, DMSO-*d*₆).



Figure S73. ¹H NMR spectrum of compound 14c' (500 MHz, DMSO- d_6).



Figure S74. ¹³C NMR spectrum of compound **14c** (126 MHz, DMSO- d_6).



Figure S75. ¹H NMR spectrum of compound **14c** (500 MHz, DMSO- d_6).



Figure S76. ¹³C NMR spectrum of compound **14c** (126 MHz, DMSO- d_6).



Figure S77. ¹H NMR spectrum of compound **14d** (500 MHz, DMSO-*d*₆).



Figure S78. ¹³C NMR spectrum of compound 14d (126 MHz, DMSO- d_6).



Figure S79. ¹H NMR spectrum of compound **14e** (500 MHz, DMSO- d_6).



Figure S80. ¹³C NMR spectrum of compound **14e** (126 MHz, DMSO- d_6).



Figure S81. ¹H NMR spectrum of compound **14f**' (500 MHz, DMSO- d_6).



Figure S82. ¹³C NMR spectrum of compound **14f** (126 MHz, DMSO- d_6).



Figure S83. ¹H NMR spectrum of compound **14f** (500 MHz, DMSO- d_6).



Figure S84. ¹³C NMR spectrum of compound **14f** (126 MHz, DMSO- d_6).



Figure S85. ¹H NMR spectrum of compound 14g' (500 MHz, DMSO- d_6).



Figure S86. ¹³C NMR spectrum of compound 14g' (126 MHz, DMSO- d_6).



Figure S87. ¹H NMR spectrum of compound **14g** (500 MHz, DMSO-*d*₆).



Figure S88. ¹³C NMR spectrum of compound **14g** (126 MHz, DMSO- d_6).



Figure S89. ¹H NMR spectrum of compound 15a (500 MHz, CDCl₃).



Figure S90. ¹³C NMR spectrum of compound 15a (126 MHz, CDCl₃).



Figure S91. ¹H NMR spectrum of compound 15b (400 MHz, CDCl₃).



Figure S92. ¹³C NMR spectrum of compound 15b (100 MHz, CDCl₃).



Figure S93. ¹H NMR spectrum of compound **16a** (500 MHz, DMSO- d_6).



Figure S94. ¹³C NMR spectrum of compound **16a** (126 MHz, DMSO- d_6).



Figure S95. ¹H NMR spectrum of compound 16b (500 MHz, DMSO-*d*₆).



Figure S96. ¹³C NMR spectrum of compound **16b** (126 MHz, DMSO- d_6).



Figure S97. ¹H NMR spectrum of compound **17a** (500 MHz, CDCl₃).


Figure S98. ¹³C NMR spectrum of compound 17a (126 MHz, CDCl₃).



Figure S99. 1 H NMR spectrum of compound 17b (500 MHz, CDCl₃).



Figure S100. ¹³C NMR spectrum of compound **17b** (126 MHz, CDCl₃).



Figure S101. ¹H NMR spectrum of compound **18a** (500 MHz, DMSO-*d*₆).



Figure S102. ¹³C NMR spectrum of compound **18a** (126 MHz, DMSO- d_6).



Figure S103. ¹H NMR spectrum of compound **18b** (500 MHz, DMSO-*d*₆).



Figure S104. ¹³C NMR spectrum of compound **18b** (126 MHz, DMSO- d_6).



Figure S105. ¹H NMR spectrum of compound S1 (500 MHz, CDCl₃).



Figure S106. ¹³C NMR spectrum of compound S1 (126 MHz, CDCl₃).



Figure S107. ¹H NMR spectrum of compound 8a (500 MHz, CDCl₃).



Figure S108. ¹³C NMR spectrum of compound 8a (126 MHz, CDCl₃).



Figure S109. ¹H NMR spectrum of compound S2 (500 MHz, CDCl₃).



Figure S110. ¹³C NMR spectrum of compound S2 (126 MHz, CDCl₃).



Figure S111. ¹H NMR spectrum of compound **S3** (400 MHz, CDCl₃).



Figure S112. ¹³C NMR spectrum of compound S3 (100 MHz, CDCl₃).



Figure S113. ¹H NMR spectrum of compound 8b (500 MHz, CDCl₃).



Figure S114. ¹³C NMR spectrum of compound 8b (126 MHz, CDCl₃).



Figure S115. ¹H NMR spectrum of compound S4 (400 MHz, CDCl₃).



Figure S116. ¹³C NMR spectrum of compound S4 (100 MHz, CDCl₃).



Figure S117. ¹H NMR spectrum of compound S5 (400 MHz, CDCl₃).



Figure S118. ¹³C NMR spectrum of compound S5 (100 MHz, CDCl₃).



Figure S119. ¹H NMR spectrum of compound **8c** (400 MHz, CDCl₃).



Figure S120. ¹³C NMR spectrum of compound 8c (100 MHz, CDCl₃).



Figure S121. ¹H NMR spectrum of compound S6 (400 MHz, CDCl₃).



Figure S122. ¹³C NMR spectrum of compound S6 (100 MHz, CDCl₃).



Figure S123. ¹H NMR spectrum of compound S7 (400 MHz, CDCl₃).



Figure S124. ¹³C NMR spectrum of compound S7 (100 MHz, CDCl₃).



Figure S125. ¹H NMR spectrum of compound S8 (500 MHz, CDCl₃).



Figure S126. ¹³C NMR spectrum of compound S8 (126 MHz, CDCl₃).



Figure S127. ¹H NMR spectrum of compound S9 (400 MHz, CDCl₃).



Figure S128. ¹³C NMR spectrum of compound S9 (100 MHz, CDCl₃).



Figure S129. ¹H NMR spectrum of compound **8e** (500 MHz, CDCl₃).



Figure S130. ¹³C NMR spectrum of compound 8e (126 MHz, CDCl₃).



Figure S131. ¹H NMR spectrum of compound S10 (400 MHz, CDCl₃).



Figure S132. ¹³C NMR spectrum of compound S10 (100 MHz, CDCl₃).



Figure S133. ¹H NMR spectrum of compound S11 (400 MHz, CDCl₃).


Figure S134. ¹³C NMR spectrum of compound S11 (100 MHz, CDCl₃).



Figure S135. ¹H NMR spectrum of compound S12 (400 MHz, CDCl₃).



Figure S136. 13 C NMR spectrum of compound S12 (100 MHz, CDCl₃).



Figure S137. ¹H NMR spectrum of compound S13 (400 MHz, CDCl₃).



Figure S138. 13 C NMR spectrum of compound S13 (100 MHz, CDCl₃).



Figure S139. ¹H NMR spectrum of compound S14 (400 MHz, CDCl₃).



Figure S140. 13 C NMR spectrum of compound S14 (100 MHz, CDCl₃).



Figure S141. ¹H NMR spectrum of compound **8f** (400 MHz, CDCl₃).



Figure S142. ¹³C NMR spectrum of compound 8f (100 MHz, CDCl₃).



Figure S143. ¹H NMR spectrum of compound S15 (500 MHz, CDCl₃).



Figure S144. 13 C NMR spectrum of compound S15 (126 MHz, CDCl₃).



Figure S145. ¹H NMR spectrum of compound S16 (500 MHz, CDCl₃).



Figure S146. 13 C NMR spectrum of compound S16 (126 MHz, CDCl₃).



Figure S147. ¹H NMR spectrum of compound S17 (500 MHz, CDCl₃).



Figure S148. 13 C NMR spectrum of compound S17 (126 MHz, CDCl₃).



Figure S149. ¹H NMR spectrum of compound S18 (400 MHz, $CDCl_3$).



Figure S150. 13 C NMR spectrum of compound S18 (100 MHz, CDCl₃).



Figure S151. ¹H NMR spectrum of compound 8g (500 MHz, CDCl₃).



Figure S152. ¹³C NMR spectrum of compound 8g (126 MHz, CDCl₃).